Osteoarthritis and Cartilage
Volume 16, Issue 9 , Pages 965-972 , September 2008

Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients? – a meta-analysis of randomized controlled trials

  • R. Christensen, M.Sc.

      Affiliations

    • The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, Denmark
    • ,
  • E.M. Bartels, Ph.D., D.Sc.

      Affiliations

    • The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, Denmark
    • Copenhagen University Library, Denmark
    • ,
  • R.D. Altman, M.D. (Professor)

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA
    • ,
  • A. Astrup, M.D., Ph.D. (Professor)

      Affiliations

    • Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Denmark
    • ,
  • H. Bliddal, M.D., Ph.D.

      Affiliations

    • The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, Denmark
    • Corresponding Author InformationAddress correspondence and reprint requests to: Professor H. Bliddal, The Parker Institute, Frederiksberg Hospital, DK-2000 F, Denmark. Tel: 45-38164151; Fax: 45-38164159.

Received 21 November 2007 ,Accepted 2 March 2008.

References 

  1. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet. 2005;365(9463):965–973
  2. Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl. 1991;27:10–12
  3. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039–1049
  4. Abramson SB. Inflammation in osteoarthritis. J Rheumatol Suppl. 2004;70:70–76
  5. Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 1997;40(4):723–727
  6. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–1155
  7. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669–681
  8. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, et al. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2004;12(4):263–268
  9. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol. 1997;24(4):799–802
  10. Tugwell P, Shea B, Boers M, Brooks P, Simon LS, Strand V, et al. Evidence-Based Rheumatology. 1st edn.. London: BMJ Books; 2004;
  11. Dougados M. Monitoring osteoarthritis progression and therapy. Osteoarthritis Cartilage. 2004;12(Suppl A):S55–S60
  12. Chrubasik C, Duke RK, Chrubasik S. The evidence for clinical efficacy of rose hip and seed: a systematic review. Phytother Res. 2006;20(1):1–3
  13. Ameye LG, Chee WS. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther. 2006;8(4):R127
  14. Winther K, Rein E, Kharazmi A. The anti-inflammatory properties of rose-hip. Inflammopharmacology. 1999;7(1):63–68
  15. Kharazmi A, Winther K. Rose hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain inflammatory parameters in vivo. Inflammopharmacology. 1999;7(4):377–386
  16. Larsen E, Kharazmi A, Christensen LP, Christensen SB. An antiinflammatory galactolipid from rose hip (Rosa canina) that inhibits chemotaxis of human peripheral blood neutrophils in vitro. J Nat Prod. 2003;66(7):994–995
  17. Orhan DD, Hartevioglu A, Küpeli E, Yesilada E. In vivo anti-inflammatory and antinociceptive activity of the crude extract and fractions from Rosa canina L. fruits. J Ethnopharmacol. 2007;112:394–400
  18. Jager AK, Eldeen IM, van SJ. COX-1 and -2 activity of rose hip. Phytother Res. 2007 Dec;21(12):1251–1252
  19. Winther K, Apel K, Thamsborg G. A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial. Scand J Rheumatol. 2005;34(4):302–308
  20. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896–1900
  21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17(1):1–12
  22. Huskisson EC. Measurement of pain. J Rheumatol. 1982;9(5):768–769
  23. Christensen R, Sørensen LB, Bartels EM, Astrup A, Bliddal H. Rose-hip in osteoarthritis (OA): a meta-analysis. Ann Rheum Dis. 2007;66(Suppl II):495;(Abstract)
  24. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002;31(1):140–149
  25. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over. Stat Med. 2002;21(15):2161–2173
  26. In:  Deeks JJ,  Higgins JPT,  Altman DG,  Higgins JPT,  Green S editor. Analysing and Presenting Results. 4.2.5. edn.. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, UK: John Wiley & Sons, Ltd; 2005;p. 97–166(Updated May 2005)
  27. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219
  28. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med. 1999;18(3):321–359
  29. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn.. Lawrence Earlbaum Associates; 1988;
  30. Hedges LV. Distribution theory for Glass's estimator of effect size and related estimators. J Educational Statistics. 1981;6(2):107–128
  31. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–592
  32. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27(Suppl 3):S178–S189
  33. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(3):377–388
  34. Bland JM, Altman DG. Statistics notes: the odds ratio. BMJ. 2000;320(7247):1468
  35. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O. SAS for Mixed Models. 2nd edn.. Cary, NC: SAS Institute Inc; 2006;
  36. Patterson HD, Thompson R. Recovery of inter-block information when block sizes are unequal. Biometrika. 1971;58(3):545–554
  37. Wang MC, Bushman BJ. Integrating Results through Meta-Analytic Review Using SAS Software. 1st edn.. Cary, NC: SAS Institute Inc; 1999;
  38. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21(4):589–624
  39. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–129
  40. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558
  41. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560
  42. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706–1713
  43. Osiri M, Suarez-Almazor ME, Wells GA, Robinson V, Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis. 2003;62(4):316–321
  44. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T. The number needed to treat for adalimumab, etanercept and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol. 2007;36(6):411–417
  45. Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol. 2002;2:1
  46. Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3
  47. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ. 2002;324(7341):827–830
  48. Visual Rx . Version 1.0–1.7. Copyright© 2000–2003. Christopher Cates; 2003;<http://www.nntonline.net>
  49. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95(5):1231–1238
  50. Rossnagel K, Willich SN. Value of complementary medicine exemplified by rose-hips. Gesundheitswesen. 2001;63(6):412–416
  51. Rein E. Hansen OT, Hansen M, Assignee. Composition and method for alleviating joint pain and stiffness. United States Patent. Patent US 6,485,752 B1. 2002 Nov 26.
  52. Warholm O, Skaar S, Hedman E, Mølmen HM, Eik L. The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: a double-blind, randomized, placebo-controlled clinical trial. Curr Ther Res Clin Exp. 2003;64(1):21–31
  53. Rein E, Kharazmi A, Winther K. A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis – a double-blind, placebo-controlled, randomised trial. Phytomedicine. 2004;11(5):383–391
  54. Ernst E. Complementary or alternative therapies for osteoarthritis. Nat Clin Pract Rheumatol. 2006;2(2):74–80
  55. Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. Phytother Res. 2007;21(7):675–683
  56. Fan X, Felsövalyi À, Sivo SA, Keenan SC. SAS for Monte Carlo Studies: a Guide for Quantitative Researchers. 3rd edn.. Cary, NC, USA: SAS Institute Inc.; 2001;
  57. Agresti A. A survey of exact inference for contingency tables. Stat Sci. 1992;7(1):131–177
  58. Thomas DG. Algorithm AS 36: exact confidence limits for the odds ratio in a 2×2 table. Appl Stat. 1971;20(1):105–110
  59. Thompson SG, Pocock SJ. Can meta-analyses be trusted?. Lancet. 1991;338(8775):1127–1130
  60. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007;15(9):981–1000
  61. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis. 2005;64(1):29–33
  62. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis. 2005;64(1):34–37
  63. Woolf AD. Healthcare services for those with musculoskeletal conditions: a rheumatology service. Recommendations of the European Union of Medical Specialists Section of Rheumatology/European Board of Rheumatology 2006. Ann Rheum Dis. 2007;66(3):293–301
  64. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000;19(22):3127–3131
  65. Towheed T, Maxwell L, Judd M, Catton M, Hochberg M, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;1:CD004257
  66. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;1469–1475
  67. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003;163(13):1514–1522
  68. Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum. 2007;56(7):2105–2110
  69. Towheed TE, Anastassiades TP. Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete. JAMA. 2000;283(11):1483–1484
  70. Towheed TE. Current status of glucosamine therapy in osteoarthritis. Arthritis Rheum. 2003;49(4):601–604
  71. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ?. Arthritis Rheum. 2007;56(7):2267–2277
  72. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663–694
  73. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134–1149
  74. Ramsey SD, Spencer AC, Topolski TD, Belza B, Patrick DL. Use of alternative therapies by older adults with osteoarthritis. Arthritis Rheum. 2001;45(3):222–227
  75. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ. 2004;329(7478):1317
  76. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004;51(5):746–754
  77. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2:CD002946
  78. Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580–590
  79. Christensen R, Bartels EM, Astrup A, Bliddal H. Symptomatic efficacy of avocado/soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007 Nov 23 [Epub ahead of print].
  80. Henrotin Y, Kurz B. Antioxidant to treat osteoarthritis: dream or reality?. Curr Drug Targets. 2007;8(2):347–357
  81. Jensen NH. Reduced pain from osteoarthritis in hip joint or knee joint during treatment with calcium ascorbate. A randomized, placebo-controlled cross-over trial in general practice. Ugeskr Laeger. 2003;165(25):2563–2566
  82. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297(8):842–857
  83. Berlin JA, Colditz GA. The role of meta-analysis in the regulatory process for foods, drugs, and devices. JAMA. 1999;281(9):830–834
  84. Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY. Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol. 2006;33(6):1152–1158
  85. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ. 1995;311(7013):1145–1148
  86. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–1840
  87. Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) – validation and comparison to the WOMAC in total knee replacement. Health Qual Life Outcomes. 2003;1(1):17
  88. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation – value in comparison with other assessment tests. Scand J Rheumatol Suppl. 1987;65:85–89
  89. Pham T, van der HD, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT–OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 2004;12(5):389–399
  90. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285(15):1987–1991

PII: S1063-4584(08)00065-4

doi: 10.1016/j.joca.2008.03.001

Osteoarthritis and Cartilage
Volume 16, Issue 9 , Pages 965-972 , September 2008

Article Tools

* Image Usage & Resolution